. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,444,920 new cancer cases and 559,650 deaths for cancers are projected to occur in the United States in 2007. Notable trends in cancer incidence and mortality rates include stabilization of the age-standardized, delay-adjusted incidence rates for all cancers combined in men from 1995 through 2003; a continuing increase in the incidence rate by 0.3% per year in women; and a 13.6% total decrease in age-standardized cancer death rates among men and women combined between 1991 and 2004. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. While the absolute number of cancer deaths decreased for the second consecutive year in the United States (by more than 3,000 from 2003 to 2004) and much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population. (CA Cancer J Clin 2007;57:43-66.)
from Cancer in North America (1999) (2000) (2001) (2002) (2003) Volume One, 6 based on data collected by cancer registries participating in the SEER program and NPCR. Population data were obtained from the US Census Bureau. 7 Causes of death were coded and classified according to the International Classification of Diseases (ICD-8, ICD-9, and ICD-10). 8, 9, 10 Cancer cases were classified according to the International Classification of Diseases for Oncology.
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Estimated New Cancer Cases
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because complete cancer registration has not yet been achieved in some states. Since the American Cancer Society (ACS) began producing estimates of new cancer cases in the current year, the method has been refined several times to take advantage of improvements in data and statistical methods. Beginning with 2007, we are using a new projection method described by Pickle et al 12 in an accompanying article in this issue of CA. The new method is a spatiotemporal model based on incidence data from 1995 through 2003 from 41 states that met NAACCR's high-quality data standard for incidence, covering about 86% of the US population. This contrasts with the previous quadratic autoregressive model based on incidence data from the nine oldest SEER registries, covering about 10% of the US population. Furthermore, the new method considers geographic variations in socio-demographic and lifestyle factors, medical settings, and cancer screening behaviors as predictors of incidence, and accounts for expected delays in case reporting.
Estimated Cancer Deaths
We used the state-space prediction method 13 to estimate the number of cancer deaths expected to occur in the United States and in each state in the year 2007. Projections are based on underlying cause-of-death from death certificates as reported to the NCHS. 1 This model projects the number of cancer deaths expected to occur in 2007 based on the number that occurred each year from 1969 to 2004 in the United States and in each state separately.
Other Statistics
We provide mortality statistics for the leading causes of death as well as deaths from cancer in the year 2004. Causes of death for 2004 were coded and classified according to This report also provides updated statistics on trends in cancer incidence and mortality rates, the probability of developing cancer, and 5-year relative survival rates for selected cancer sites based on data from 1975 through 2003. 3 All age-adjusted incidence and death rates are standardized to the 2000 US standard population and expressed per 100,000 population.
The long-term incidence rates and trends (1975 to 2003) are adjusted for delays in reporting where possible. Delayed reporting affects the most recent 1 to 3 years of incidence data (in this case, 2001 to 2003), especially for cancers such as melanoma and prostate that are frequently diagnosed in outpatient settings. The National Cancer Institute (NCI) has developed a method to account for expected reporting delays in SEER registries for all cancer sites combined and several specific cancer sites when long-term incidence trends are analyzed.
14 Delay-adjusted trends provide a more accurate assessment of trends in the most recent years for which data are available. Melanoma-skin  59,940  33,910  26,030  8,110  5,220  2,890  Other nonepithelial skin  5,110  3,160  1,950  2,740  1,920  820  Breast  180,510  2,030  178,480  40,910  450  40,460  Genital system  306,380  228,090  78,290  55,740  27,720  28,020  Uterine cervix  11,150  11,150  3,670  3,670  Uterine corpus  39,080  39,080  7,400  7,400  Ovary  22,430  22,430  15,280  15,280  Vulva  3,490  3,490  880  880  Vagina & other genital, female  2,140  2,140  790  790  Prostate  218,890  218,890  27,050  27,050  Testis  7,920  7,920  380  380  Penis & other genital, male  1,280  1,280  290  290  Urinary system  120,400  82,960  37,440  27,340  18,100  9,240  Urinary bladder  67,160  50,040  17,120  13,750  9,630  4,120  Kidney & renal pelvis  51,190  31,590  19,600  12,890  8,080  4,810  Ureter & other urinary organs  2,050  1,330  720  700  390  310  Eye & orbit  2,340  1,310  1,030  220  110  110  Brain & other nervous system  20,500  11,170  9,330  12,740  7,150  5,590  Endocrine system  35,520  9,040  26,480  2,320  1,030  1,290  Thyroid  33,550  8,070  25,480  1,530  650  880  Other endocrine  1,970  970  1,000  790  380  410  Lymphoma  71,380  38,670  32,710  19,730  10, AL  429.0  20,590  2,750  170  2,350  460  550  3,850  740  860  3,010  850  AK  480.7  2,500  340   ‡  270  60  70  330  80  110  420  110  AZ   §  26,270  3,220  190  2,750  550  740  3,740  1,300  1,080  3,400  1,360  AR   §  14,130  1,830  130  1,640  320  510  2,420  550 Figure 1 indicates the most common cancers expected to occur in men and women in 2007. Among men, cancers of the prostate, lung and bronchus, and colon and rectum account for about 54% of all newly diagnosed cancers. Prostate cancer alone accounts for about 29% (218,890) of incident cases in men. Based on cases diagnosed between 1996 and 2002, an estimated 91% of these new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which 5-year relative survival approaches 100%.
SELECTED FINDINGS
Expected Numbers of New Cancer Cases
The three most commonly diagnosed types of cancer among women in 2007 will be cancers of the breast, lung and bronchus, and colon and rectum, accounting for about 52% of estimated cancer cases in women. Breast cancer alone is expected to account for 26% (178,480) of all new cancer cases among women. women, and both sexes combined. It is estimated that about 559,650 Americans will die from cancer, corresponding to over 1,500 deaths per day. Cancers of the lung and bronchus, prostate, and colon and rectum in men, and cancers of the lung and bronchus, breast, and colon and rectum in women continue to be the most common fatal cancers. These four cancers account for half of the total cancer deaths among men and women ( Figure 1 ). Lung cancer surpassed breast cancer as the leading cause of cancer death in women in 1987. Lung cancer is expected to account for 26% of all female cancer deaths in 2007. Table 3 provides the estimated number of cancer deaths in 2007 by state for selected cancer sites. Table  4 , the largest variations in the incidence rates, in proportionate terms, occurred in lung cancer, in which rates (cases per 100,000 population) ranged from 41.8 in men and 21.5 in women in Utah to 137.9 in men and 73.5 in women in Kentucky. In contrast, the variation in female breast cancer incidence rates was small, ranging from 115 cases per 100,000 population in New Mexico to 146.7 cases in Washington. Factors that contribute to the state variations in the incidence rates include differences in the prevalence of risk factors, access to and utilization of early detection services, and completeness of reporting. For example, the state variation in lung cancer incidence rates primarily reflects differences in smoking prevalence; Utah ranks lowest in adult smoking prevalence and Kentucky highest.
Expected Number of New Cancer Deaths
Regional Variations in Cancer Rates
Trends in Cancer Incidence and Mortality
Figures 2 to 5 depict long-term trends in cancer incidence and death rates for all cancers combined and for selected cancer sites by sex. Table 5 shows incidence and mortality patterns for all cancer sites combined and for the four most common cancer sites based on joinpoint analysis. Trends in incidence were adjusted for delayed reporting. Delay-adjusted cancer incidence rates for all sites combined stabilized in men from 1995 to 2003 and increased in women by 0.3% per year from 1987 to 2003.
Lung cancer incidence rates are declining in men and appear to be plateauing in women after increasing for many decades. The lag in the temporal trend of lung cancer incidence rates in women compared with men reflects historical differences in cigarette smoking between men and women; cigarette smoking in women peaked about 20 years later than in men. Colorectal cancer incidence rates have decreased from 1998 through 2003 in both males and in females. Female breast cancer incidence rates leveled off from 2001 to 2003 after increasing since 1980, which may reflect the saturation of mammography utilization and reduction in the use of hormone replacement therapy. 15 Prostate cancer incidence rates continued to increase, although at a slower rate than those reported for the early 1990s and before. The continuing increase for prostate cancer may be attributable to increased screening through prostate-specific antigen (PSA) testing. 15 Death rates for all cancer sites combined decreased by 1.6% per year from 1993 to 2003 in males and by 0.8% per year in females from 1992 to 2003. Mortality rates have continued to decrease across all four major cancer sites in men and in women, except for female lung cancer in which rates continued to increase by 0.3% per year from 1995 to 2003 (Table 5) . Table 6 shows the contribution of individual cancer sites to the total decrease in overall cancer death rates. Death rates from all cancers combined peaked in 1990 for men and in 1991 for women. Between 1990/1991 and 2003, death rates from cancer decreased by 16.3% among men and by 8.5% among women. Among men, reduction in death rates from lung, prostate, and colorectal cancers accounts for about 80% of the decrease in cancer death rates, while reduction in death rates from breast and colorectal cancers accounts for over 60% of the decrease among women. Lung cancer in men and breast cancer in women alone account for nearly 40% of the sex-specific decreases in cancer death rates. The decrease in lung cancer death rates among men is due to reduction in tobacco use over the past 40 years, while the decrease in death rates from female breast, colorectal, and prostate cancer largely reflects improvements in early detection and treatment. in 20-year age intervals, cancer is one of the five leading causes of death in each age group among both males and females (Table 8) . Cancer is the leading cause of death among women aged 40 to 79 years and among men aged 60 to 79 years. When age-adjusted death rates are considered (Figure 6 Table 9 presents the number of deaths from all cancers combined and the five most common cancer sites for males and females at various ages. Among males under age 40 years, leukemia is the most common fatal cancer, while cancer of the lung and bronchus predominates in men aged 40 years and older. The second most common cause of cancer death is colorectal cancer among men aged 40 to 79 years and prostate cancer among men aged 80 years and older. Among females, leukemia is the leading cause of cancer death before age 20 years, breast cancer ranks first at age 20 to 59 years, and lung cancer ranks first at age 60 years and older.
From 2003 to 2004, the number of recorded cancer deaths decreased by 1,160 in men and by 1,854 in women (Table 10 ). The largest change in number of deaths from the major cancers was for colorectal cancer in both men and women (decreased by 1,110 and 1,094, respectively).
CANCER OCCURRENCE BY RACE/ETHNICITY
Cancer incidence and death rates vary considerably among racial and ethnic groups (Table 11) . For all cancer sites combined, African American men have a 15% higher incidence rate and 38% higher death rate than White men. African American women have a 9% lower incidence rate, but an 18% higher death rate than White women for all cancer sites combined. For the specific cancer sites listed in Table 11 , incidence and death rates are consistently higher in African Americans than in Whites, except for breast cancer (incidence) and lung and kidney cancers (incidence and mortality) among women. Death rates from prostate, stomach, and cervical cancers among African Americans are more than twice those in Whites. Factors known to contribute to racial disparities in mortality vary by cancer site. These factors include differences in exposure to underlying risk factors (eg, Helicobacter pylori for stomach cancer), access to high-quality regular screening (breast, cervical, and colorectal cancers), and timely diagnosis and treatment (for many cancers). The higher breast cancer incidence rates among Whites are thought to reflect a combination of factors that affect diagnosis (such as more frequent mammography in White women until the most recent time period) and those that affect disease risk (such as later age at first birth and greater use of hormone replacement therapy among White than African American women). 16 Among other racial and ethnic groups, cancer incidence and death rates are lower than those in Whites and African Americans for all cancer sites combined and for the four most common cancer sites. However, the incidence and death rates are generally higher in minority populations than in Whites for cancers of the uterine cervix, stomach, and liver. Stomach and liver cancer incidence and death rates are more than twice as high in Asian American/Pacific Islanders as in Whites, reflecting increased exposure to infectious agents such as Helicobacter pylori and hepatitis B. 17 Kidney cancer incidence and death rates are the highest among American Indians/ Alaskan Natives, although factors that contribute to this are unknown.
Trends in cancer incidence can only be adjusted for delayed reporting in Whites and African Americans, and not in other racial and ethnic subgroups, because long-term incidence data required for delay adjustment are available only for Whites and African Americans. From 1995 to 2003, sex-specific incidence rates for all cancer sites combined, not adjusted for delayed reporting, have stabilized, except for African American and Hispanic men, in whom rates decreased by 1.3% and 1.1%, respectively. In contrast, death rates from cancer significantly decreased in each racial and ethnic group, with larger decreases in men than in women. The lifetime probability of developing cancer is higher for men (45%) than for women (38%) ( Table 12 ). However, because of the relatively early age of breast cancer onset, women have a slightly higher probability of developing cancer before age 60 years. It is noteworthy that these estimates are based on the average experience of the general population and may over-or underestimate individual risk because of differences in exposure and/or genetic susceptibility.
Cancer Survival by Race
Compared with Whites, African American men and women have poorer survival once a cancer diagnosis is made. As shown in Figure 7 , African Americans are less likely than Whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated, and are more likely to be diagnosed with cancer at a regional or distant stage of disease. Five-year relative survival is lower in African Americans than Whites within each stratum of stage of diagnosis for nearly every cancer site (Figure 8 ). These disparities may result from inequalities in access to and receipt of quality health care and/or within-stage differences in tumor characteristics. The contribution of these factors, individually or collectively, to the differential survival for specific cancers is unclear. 18 However, some studies suggest that African *Death rates from cancer peaked in 1990 for men and in 1991 for women. †This calculation is based on each cancer site's contribution to the increasing or decreasing portion of the total cancer death rate, depending on the individual site's trend; it does not represent the contribution to the net decrease in cancer death rates. Americans who receive cancer treatment and medical care similar to that of Whites experience similar outcomes.
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There have been notable improvements over time in relative 5-year survival rates for many cancer sites and for all cancers combined (Table  13 ). This is true for both Whites and African Americans. Cancers for which survival has not improved substantially over the past 25 years include uterine corpus, cervix, larynx, lung, and pancreas.
Relative survival rates cannot be calculated for other racial and ethnic populations because accurate life expectancies (the average number of years of life remaining for persons who have attained a given age) are not available. However, based on cause-specific survival rates of cancer patients diagnosed from 1992 to 2000 in SEER areas of the United States, all minority populations, except Asian American/Pacific Islander women, have a greater probability of dying from cancer within 5 years of diagnosis than nonHispanic Whites, after accounting for differences in stage at diagnosis. 15, 20 For the four major cancer sites (prostate, female breast, lung and bronchus, and colon and rectum), minority populations are more likely to be diagnosed at distant stage, compared with non-Hispanic Whites. 20 
CANCER IN CHILDREN
Cancer is the second leading cause of death among children between age 1 to 14 years in the United States; accidents are the most frequent cause of death in this age group (Table  14) . The most common cancers in children (aged 0 to 14 years) are leukemia (particularly acute lymphocytic leukemia), brain and other nervous system cancers, soft tissue sarcomas, nonHodgkin lymphoma, and renal (Wilms) tumors. 3 Over the past 25 years, there have been significant improvements in the 5-year relative survival rate for many childhood cancers ( Estimates of the expected numbers of new cancer cases and cancer deaths should be interpreted cautiously. These estimates may vary considerably from year to year, particularly for less common cancers and in states with smaller populations. Unanticipated changes may occur that are not captured by modeling techniques. Estimates are also affected by changes in method. The introduction of a new method for estimating new cancer cases in 2007 has substantially affected the estimates for a number of cancers, particularly leukemia and female breast (see Pickle et al for more detailed discussion). 12 For these reasons, we discourage the use of these estimates to track year-to-year changes in cancer occurrence and death. Age-standardized or age-specific cancer death rates from the NCHS and cancer incidence rates from SEER or NPCR are the preferred data sources for tracking cancer trends, even though these data are 3 and 4 years old, respectively, by the time that they become available. Despite their limitations, the ACS estimates of the number of new cancer cases and deaths in the current year provide reasonably accurate estimates of the burden of new cancer cases and deaths in the United States. Such estimates will assist in continuing efforts to reduce the public health burden of cancer.
